BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9052419)

  • 1. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
    Papamichael D; Gallagher CJ; Oliver RT; Johnson PW; Waxman J
    Br J Cancer; 1997; 75(4):606-7. PubMed ID: 9052419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy.
    Dreicer R; Gustin DM; See WA; Williams RD
    J Urol; 1996 Nov; 156(5):1606-8. PubMed ID: 8863548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.
    Ko YJ; Canil CM; Mukherjee SD; Winquist E; Elser C; Eisen A; Reaume MN; Zhang L; Sridhar SS
    Lancet Oncol; 2013 Jul; 14(8):769-76. PubMed ID: 23706985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer.
    Burch PA; Richardson RL; Cha SS; Sargent DJ; Pitot HC; Kaur JS; Camoriano JK
    J Urol; 2000 Nov; 164(5):1538-42. PubMed ID: 11025699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combination.
    Nichols RC; Sweetser MG; Mahmood SK; Malamud FC; Dunn NP; Adams JP; Kyker JS; Lydick K
    Int J Cancer; 2000 Oct; 90(5):281-6. PubMed ID: 11091352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of a new combined primary chemotherapy regimen, intravenous methotrexate and vincristine and intraarterial adriamycin and cisplatin, for locally advanced urinary bladder cancer: preliminary results.
    Kuroiwa T; Naito S; Hasuo K; Kishikawa T; Masuda K; Kumazawa J
    Cancer Chemother Pharmacol; 1995; 35(5):357-63. PubMed ID: 7850915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CMV chemotherapy for advanced transitional cell carcinoma.
    Jeffery GM; Mead GM
    Br J Cancer; 1992 Sep; 66(3):542-6. PubMed ID: 1520591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.
    Vaughn DJ; Broome CM; Hussain M; Gutheil JC; Markowitz AB
    J Clin Oncol; 2002 Feb; 20(4):937-40. PubMed ID: 11844814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.
    Kitamura H; Taguchi K; Kunishima Y; Yanase M; Takahashi A; Shigyo M; Tanaka T; Mutoh M; Fukuta F; Masumori N; Tsukamoto T
    Cancer Sci; 2011 Jun; 102(6):1171-5. PubMed ID: 21323791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):55-8. PubMed ID: 8941411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
    Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
    J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.
    Roth BJ; Dreicer R; Einhorn LH; Neuberg D; Johnson DH; Smith JL; Hudes GR; Schultz SM; Loehrer PJ
    J Clin Oncol; 1994 Nov; 12(11):2264-70. PubMed ID: 7525883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Arterial infusion chemotherapy for patients with advanced and moderately advanced cancer of urinary bladder].
    Li Q; Xu X; Liu J
    Zhonghua Zhong Liu Za Zhi; 1998 Jul; 20(4):308-9. PubMed ID: 10920993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activity of paclitaxel in gastrointestinal tumors.
    Ajani JA; Ilson DH; Kelsen DP
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PubMed ID: 7481861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.
    Winquist E; Moore MJ; Chi KN; Ernst DS; Hirte H; North S; Powers J; Walsh W; Boucher T; Patton R; Seymour L
    Urol Oncol; 2005; 23(3):143-9. PubMed ID: 15907712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-GuĂ©rin treatment failure.
    McKiernan JM; Holder DD; Ghandour RA; Barlow LJ; Ahn JJ; Kates M; Badalato GM; Roychoudhury A; Decastro GJ; Benson MC
    J Urol; 2014 Dec; 192(6):1633-8. PubMed ID: 24996128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer].
    Yamauchi T; Hida S; Ooishi K; Okada K; Yoshida O
    Hinyokika Kiyo; 1985 Jul; 31(7):1093-104. PubMed ID: 2414981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.